Update in asthma pharmacotherapy

Asthma update.

Asthma continues to be one of the most common reasons for emergency department visits and a leading cause of hospitalization. Acute management involves severity-based treatment of bronchoconstriction and underlying airway inflammation. Optimal treatment has been defined and standardized through randomized controlled trials, systematic reviews, and consensus guidelines. Implementation of clinica...

An update on pharmacotherapy of vertigo

Vertigo is a specific symptom directly related to dysfunction of vestibular system. It is most common complaint, especially in elderly age group that leads them to visit their physicians. There is no ideal drug for the management of vertigo. The pharmacotherapy of vertigo can be optimized with detailed knowledge of the drugs effective in vertigo and their limitations. In this article, we will d...

Update on pharmacotherapy for pulmonary hypertension.

Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways. Treatment with these therapies in specialised pulmonary hypertension centres has resu...

New intravenous antibiotics: a focused pharmacotherapy update.

Infections due to multidrug-resistant pathogens are increasing throughout the world, in particular due to the emergence of resistant Staphylococcus aureus, vancomycin-resistant enterococcus (VRE) penicillin-resistant Streptococcus pneumonia, multidrug-resistant (MDR) Pseudomonas and Acinetobacter spp, extended-spectrum β-lactamase(ESBL) producing enteric organisms, etc. These serious pathogens ...

Pharmacotherapy--treatment of intermittent asthma with ICSs.